Investors
Our investor proposition
GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products.
Key information
2020 Second quarter results announcement
We announced our second quarter results for the period ended 30 June 2020 on Wednesday 29 July.
Latest information
Press releases for media
- FDA approves Nucala as the first and only biologic treatment for Hypereosinophilic Syndrome (HES)
- Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
- GSK receives CHMP positive opinion recommending approval of Zejula (niraparib) as first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer
- Sanofi and GSK confirm agreement with European Union to supply up to 300 million doses of adjuvanted COVID-19 vaccine
Annual Report 2019
We published our Annual Report 2019 on 04 March 2020. View the summary and download the full report or individual sections.